| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 6576- | EU, | Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53 |
| - | in-vitro, | HCC, | HepG2 |
| 6578- | EU, | Eurycomanol and eurycomanone as potent inducers for cell-cycle arrest and apoptosis in small and large human lung cancer cell lines |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 |
| 6579- | EU, | Eurycomanone and Eurycomanol from Eurycoma longifolia Jack as Regulators of Signaling Pathways Involved in Proliferation, Cell Death and Inflammation |
| - | in-vitro, | AML, | K562 |
| 6584- | EU, | Eurycoma longifolia: an overview on the pharmacological properties for the treatment of common cancer |
| - | Review, | Var, | NA |
| 6377- | Eug, | Pharmacological Properties and Health Benefits of Eugenol: A Comprehensive Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6389- | Eug, | Molecular Insights into the Management of Eugenol's Anticancer Action Against Colon Cancer: A Detailed Review |
| - | Review, | Colon, | NA |
| 6387- | Eug, | Anticancer and antibacterial effects of a clove bud essential oil-based nanoscale emulsion system |
| - | in-vitro, | Thyroid, | NA | - | in-vitro, | Nor, | HEK293 |
| 6388- | Eug, | Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review |
| - | Review, | Var, | NA |
| 6845- | EVO, | Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo |
| - | vitro+vivo, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6840- | EVO, | Evodiamine Induces G2/M Arrest and Apoptosis via Mitochondrial and Endoplasmic Reticulum Pathways in H446 and H1688 Human Small-Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | H446 | - | in-vitro, | Lung, | H1688 |
| 2497- | FBZ, | In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells |
| - | in-vitro, | GBM, | NA |
| 2496- | FBZ, | Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 6856- | FBZ, | Fenbendazole Suppresses Growth and Induces Apoptosis of Actively Growing H4IIE Hepatocellular Carcinoma Cells via p21-Mediated Cell-Cycle Arrest |
| - | in-vitro, | Liver, | H4IIE |
| 6853- | FBZ, | Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 6854- | FBZ, | Fenbendazole and its synthetic analog interfere with HeLa cells' proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway |
| - | in-vitro, | Cerv, | HeLa |
| 6426- | FEO, | Foeniculum Vulgare and Pelargonium Graveolens Essential Oil Mixture Triggers the Cell Cycle Arrest and Apoptosis in MCF-7 Cells |
| - | in-vitro, | BC, | MCF7 |
| 6892- | Fer, | MR Imaging of Tumor Associated Macrophages with Clinically-Applicable Iron Oxide Nanoparticles |
| - | in-vivo, | Var, | NA |
| 2851- | FIS, | Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | Nor, | NA |
| 2852- | FIS, | A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms |
| - | Review, | CRC, | NA |
| 2860- | FIS, | Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vivo, | NA, | NA |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2833- | FIS, | AgNPs, | Glucose-capped fisetin silver nanoparticles induced cytotoxicity and ferroptosis in breast cancer cells: A molecular perspective |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2842- | FIS, | Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 6911- | FIS, | New Mitochondria-Targeted Fisetin Derivative Compromises Mitophagy and Limits Survival of Drug-Induced Senescent Breast Cancer Cells |
| - | vitro+vivo, | BC, | NA |
| 6901- | FIS, | Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC |
| - | in-vivo, | HNSCC, | CAL33 |
| 6899- | FIS, | Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 6896- | FIS, | Fisetin is a senotherapeutic that extends health and lifespan |
| - | in-vivo, | Nor, | NA |
| 6969- | Form, | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | HCC827 | - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 7020- | Fuc, | Systematic synthesis of low-molecular weight fucoidan derivatives and their effect on cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | WI38 |
| 7009- | Fuc, | Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF12A |
| - | in-vitro, | Oral, | NA |
| 4025- | FulvicA, | Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | Review, | AD, | NA |
| 4027- | FulvicA, | Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 7041- | GA, | Gallic acid suppresses the progression of clear cell renal cell carcinoma through inducing autophagy via the PI3K/Akt/Atg16L1 signaling pathway |
| - | vitro+vivo, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | Nor, | HK-2 |
| 7037- | GA, | Chit, | Gallic acid-loaded chitosan nanoparticles enhance the DNA damage and apoptotic features through inhibiting flap endonuclease-1 in triple-negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | NSCLC, | A549 |
| 7032- | GA, | Cisplatin, | Gallic acid: a polyphenolic compound potentiates the therapeutic efficacy of cisplatin in human breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 7033- | GA, | OL, | Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line |
| - | in-vitro, | OS, | U2OS |
| 7029- | GA, | Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | Nor, | MCF10 |
| 1971- | GamB, | Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vivo, | NA, | NA |
| 5149- | GamB, | Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells |
| - | in-vitro, | lymphoma, | JeKo-1 |
| 7088- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC4 |
| 7233- | GAs, | Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis |
| - | in-vitro, | Laryn, | HEp2 |
| 7216- | GBE, | Cytotoxic effect of Ginkgo biloba kernel extract on HCT116 and A2058 cancer cell lines |
| - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | CRC, | HCT116 |
| 7226- | GBE, | Ginkgo biloba exocarp extracts induces apoptosis in Lewis lung cancer cells involving MAPK signaling pathways |
| - | vitro+vivo, | Lung, | NA |
| 7100- | Geld, | Rad, | Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin |
| - | in-vitro, | Var, | NA |
| 7095- | Geld, | Mechanistic studies on Hsp90 inhibition by ansamycin derivatives |
| - | Study, | Var, | NA |
| 7103- | GEN, | A Comprehensive Review of Genistein's Effects in Preclinical Models of Cervical Cancer |
| - | Review, | Cerv, | NA |
| 6562- | Ger, | Potential Effects of Geraniol on Cancer and Inflammation-Related Diseases: A Review of the Recent Research Findings |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 7252- | Gink, | STEAP2-associated modulation of PI3K/AKT/mTOR signaling contributes to ginkgetin-induced apoptosis in bladder cancer cells |
| - | in-vitro, | Bladder, | 5637 | - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 | - | in-vitro, | Nor, | SV-HUC-1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid